Double placebo design in a prevention trial for Alzheimer's disease

Barbara K. Martin, Curtis L. Meinert, John C.S. Breitner

Research output: Contribution to journalArticlepeer-review

Abstract

The Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) is designed to compare two nonsteroidal anti-inflammatory agents against placebo. A placebo control for two active treatments can be achieved in several ways, each of which may have different implications for the logistics of drug supply, enrollment, adherence to treatment, and the validity of specific treatment comparisons. The authors outline the placebo designs considered in ADAPT, discuss their advantages and disadvantages, and provide their rationale for and the consequences of the selection of the double placebo design.

Original languageEnglish (US)
Pages (from-to)93-99
Number of pages7
JournalControlled clinical trials
Volume23
Issue number1
DOIs
StatePublished - 2002

Keywords

  • Alzheimer's disease
  • Placebo control
  • Primary prevention
  • Randomized clinical trial

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Double placebo design in a prevention trial for Alzheimer's disease'. Together they form a unique fingerprint.

Cite this